Ep 52: COLUMBUS 7-year follow-up

Summary

In this episode of Melanoma Matters, James tells us about his path to oncology (thank you, Emma) via John Newsom-Davis, the Jeremy Bentham pub, and Hammersmith Hospital.

Later, hosts Sapna Patel and James Larkin discuss the COLUMBUS 7-year data of targeted therapy for metastatic melanoma - treatment efficacy, toxicity, and long-term patient management. They explore the nuances of treatment strategies, the importance of biomarkers, and the challenges of monitoring long-term patients on targeted therapies.

Takeaways

Time to next therapy is a valuable metric for assessing treatment success.

Long-term treatment decisions should consider patient quality of life.

Biomarkers are crucial for determining the duration of targeted therapy.

Compliance in clinical trials may not reflect real-world scenarios.

Monitoring for long-term toxicity is necessary for patients on extended therapy.

The combination of BRAF and MEK inhibitors may improve tolerability despite the COLUMBUS study showing a higher toxicity rate in the combination arm.

Congratulations to the European colleagues who led and executed this trial.

Keywords

BRAF MEK, targeted therapy, COLUMBUS study, melanoma, treatment efficacy, toxicity, long-term care, patient management

Titles

Exploring the COLUMBUS 7-Year Data

Oncology Journeys: Personal Stories and Insights

Sound Bites

"We need to know even the low-grade toxicities."

"There's nothing wrong with improving side effects."

"Kudos to our mainland European colleagues."

Chapters

00:00 Introduction

06:12 COLUMBUS 7-Year Overview

12:15 Historical context on study arms

17:55 Long-Term Treatment Considerations

21:29 Desperate... for a Biomarker

23:43 Any insights into development of CNS disease?

30:47 Fact Check for COLUMBUS 7-Year follow-up

32:50 Time to End of Next Line of Treatment in COLUMBUS (akin to PFS2)

35:32 Toxicity & Discontinuation Rate in COLUMBUS